Cargando…
Analogue-based drug discovery III /
"Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the succe...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Weinheim :
Wiley-VCH,
[2013]
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | EBOOKCENTRAL_ocn826637765 | ||
| 003 | OCoLC | ||
| 005 | 20240329122006.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 130204t20132013gw ac ob 001 0 eng d | ||
| 040 | |a DG1 |b eng |e rda |e pn |c DG1 |d EBLCP |d N$T |d MHW |d YDXCP |d COO |d IDEBK |d E7B |d NOC |d OCLCF |d IUL |d SCB |d OCLCQ |d CDX |d NKT |d OCLCQ |d DG1 |d MOR |d CCO |d LIP |d PIFAG |d OCLCQ |d MERUC |d OCLCQ |d ZCU |d U3W |d COCUF |d OCLCQ |d CASUM |d OCLCO |d STF |d WRM |d ICG |d VT2 |d OCLCQ |d DKC |d OCLCO |d OCLCQ |d UKAHL |d OL$ |d OCLCQ |d OCLCA |d UKCRE |d VLY |d OCLCO |d VHC |d OCLCO |d OCL |d OCLCQ |d OCLCO |d OCLCQ | ||
| 019 | |a 828869678 |a 828896125 |a 961601655 |a 962705463 |a 988462381 |a 992078229 |a 1037713884 |a 1038676031 |a 1045504346 |a 1055343596 |a 1081183401 |a 1153479029 |a 1162545768 |a 1228618788 |a 1290046792 |a 1303445841 | ||
| 020 | |a 9783527651085 |q (electronic bk.) | ||
| 020 | |a 352765108X |q (electronic bk.) | ||
| 020 | |a 9783527651115 |q (electronic bk.) | ||
| 020 | |a 352765111X |q (electronic bk.) | ||
| 020 | |a 9781299241206 |q (MyiLibrary) | ||
| 020 | |a 1299241204 |q (MyiLibrary) | ||
| 020 | |z 9783527330737 | ||
| 020 | |z 3527330739 | ||
| 020 | |a 3527651101 | ||
| 020 | |a 9783527651108 | ||
| 029 | 1 | |a AU@ |b 000050562533 | |
| 029 | 1 | |a AU@ |b 000053030546 | |
| 029 | 1 | |a AU@ |b 000060490866 | |
| 029 | 1 | |a CHNEW |b 000941069 | |
| 029 | 1 | |a CHVBK |b 480213402 | |
| 029 | 1 | |a DEBBG |b BV043395341 | |
| 029 | 1 | |a DEBBG |b BV044050030 | |
| 029 | 1 | |a DEBSZ |b 485030942 | |
| 029 | 1 | |a NZ1 |b 15340091 | |
| 035 | |a (OCoLC)826637765 |z (OCoLC)828869678 |z (OCoLC)828896125 |z (OCoLC)961601655 |z (OCoLC)962705463 |z (OCoLC)988462381 |z (OCoLC)992078229 |z (OCoLC)1037713884 |z (OCoLC)1038676031 |z (OCoLC)1045504346 |z (OCoLC)1055343596 |z (OCoLC)1081183401 |z (OCoLC)1153479029 |z (OCoLC)1162545768 |z (OCoLC)1228618788 |z (OCoLC)1290046792 |z (OCoLC)1303445841 | ||
| 037 | |a 455370 |b MIL | ||
| 050 | 4 | |a RM301.25 |b .A53 2013 | |
| 072 | 7 | |a MED |x 023000 |2 bisacsh | |
| 072 | 7 | |a MED |x 058170 |2 bisacsh | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 072 | 7 | |a MED |x 072000 |2 bisacsh | |
| 072 | 7 | |a HEA |2 eflch | |
| 082 | 0 | 4 | |a 615.1/9 |2 23 |
| 049 | |a UAMI | ||
| 245 | 0 | 0 | |a Analogue-based drug discovery III / |c edited by János Fischer, C. Robin Ganellin, David P. Rotella. |
| 246 | 3 | |a Analogue-based drug discovery 3 | |
| 246 | 3 | |a Analog-based drug discovery III | |
| 264 | 1 | |a Weinheim : |b Wiley-VCH, |c [2013] | |
| 264 | 4 | |c ©2013 | |
| 300 | |a 1 online resource (xviii, 385 pages) : |b illustrations, portraits | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 588 | 0 | |a Online resource; title page from PDF title page (viewed June 30, 2014). | |
| 505 | 0 | 0 | |t General Aspects. Pioneer and Analogue Drugs / |r Janos Fischer, C Robin Ganellin, David P Rotella -- |t Competition in the Pharmaceutical Drug Development / |r Christian Tyrchan, Fabrizio Giordanetto -- |t Metabolic Stability and Analogue-Based Drug Discovery / |r Amit S Kalgutkar, Antonia F Stepan -- |t Use of Macrocycles in Drug Design Exemplified with Ulimorelin, a Potential Ghrelin Agonist for Gastrointestinal Motility Disorders / |r Mark L Peterson, Hamid Hoveyda, Graeme Fraser, Eric Marsault, Rene Gagnon -- |t Drug Classes. The Discovery of Anticancer Drugs Targeting Epigenetic Enzymes / |r A Ganesan -- |t Thienopyridyl and Direct-Acting P2Y Receptor Antagonist Antiplatelet Drugs / |r Joseph A Jakubowski, Atsuhiro Sugidachi -- |t Selective Estrogen Receptor Modulators / |r Amarjit Luniwal, Rachael Jetson, Paul Erhardt -- |t Discovery of Nonpeptide Vasopressin V2 Receptor Antagonists / |r Kazumi Kondo, Hidenori Ogawa -- |t The Development of Cysteinyl Leukotriene Receptor Antagonists / |r Peter R Bernstein -- |t Case Studies. The Discovery of Dabigatran Etexilate / |r Norbert Hauel, Andreas Clemens, Herbert Nar, Henning Priepke, Joanne van Ryn, Wolfgang Wienen -- |t The Discovery of Citalopram and Its Refinement to Escitalopram / |r Klaus P Bogeso, Connie Sanchez -- |t Tapentadol : From Morphine and Tramadol to the Discovery of Tapentadol / |r Helmut Buschmann -- |t Novel Taxanes: Cabazitaxel Case Study / |r Herve Bouchard, Dorothee Semiond, Marie-Laure Risse, Patricia Vrignaud -- |t Discovery of Boceprevir and Narlaprevir: A Case Study for Role of Structure-Based Drug Design / |r Srikanth Venkatraman, Andrew Prongay, George F Njoroge -- |t A New-Generation Uric Acid Production Inhibitor: Febuxostat / |r Ken Okamoto, Shiro Kondo, Takeshi Nishino. |
| 504 | |a Includes bibliographical references and index. | ||
| 520 | |a "Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs. The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtually every researcher in drug discovery and pharmaceutical chemistry, and--together with the previous volumes--constitutes the first systematic approach to drug analogue development"--Publisher's website. | ||
| 546 | |a English. | ||
| 590 | |a ProQuest Ebook Central |b Ebook Central Academic Complete | ||
| 650 | 0 | |a Drug development. | |
| 650 | 0 | |a Drugs |x Design. | |
| 650 | 1 | 2 | |a Pharmaceutical Preparations |x chemical synthesis |
| 650 | 2 | 2 | |a Drug Design |
| 650 | 2 | 2 | |a Models, Molecular |
| 650 | 6 | |a Médicaments |x Développement. | |
| 650 | 6 | |a Médicaments |x Conception. | |
| 650 | 7 | |a MEDICAL |x Drug Guides. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Nursing |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Pharmacy. |2 bisacsh | |
| 650 | 7 | |a Drugs |x Design |2 fast | |
| 650 | 7 | |a Drug development |2 fast | |
| 655 | 4 | |a Internet Resources. | |
| 655 | 4 | |a Portraits. | |
| 700 | 1 | |a Fischer, János, |e editor. | |
| 700 | 1 | |a Ganellin, C. R. |q (C. Robin), |e editor. | |
| 700 | 1 | |a Rotella, David P., |e editor. | |
| 776 | 0 | 8 | |i Print version: |t Analogue-based drug discovery III. |d Weinheim : Wiley-VCH, [2013] |z 9783527330737 |w (OCoLC)825555931 |
| 856 | 4 | 0 | |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=1123660 |z Texto completo |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH25007714 | ||
| 938 | |a Askews and Holts Library Services |b ASKH |n AH24977382 | ||
| 938 | |a Coutts Information Services |b COUT |n 24876696 |c 130.00 GBP | ||
| 938 | |a EBL - Ebook Library |b EBLB |n EBL1123660 | ||
| 938 | |a ebrary |b EBRY |n ebr10662582 | ||
| 938 | |a EBSCOhost |b EBSC |n 542882 | ||
| 938 | |a ProQuest MyiLibrary Digital eBook Collection |b IDEB |n cis24876696 | ||
| 938 | |a YBP Library Services |b YANK |n 9985301 | ||
| 938 | |a YBP Library Services |b YANK |n 10226219 | ||
| 938 | |a YBP Library Services |b YANK |n 10247713 | ||
| 994 | |a 92 |b IZTAP | ||